timothy sykes logo

Stock News

ProKidney’s Dramatic Shares Tumble

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Tim Sykes Fact-checked by Matt Monaco
Updated 7/15/2025, 5:03 pm ET 7/15/2025, 5:03 pm ET | 5 min 5 min read
ProKidney’s Dramatic Shares Tumble Thumbnail

On Tuesday, ProKidney Corp.’s stocks have been trading down by -8.13 percent, potentially influenced by market sentiment.

Candlestick Chart

Live Update At 17:03:11 EST: On Tuesday, July 15, 2025 ProKidney Corp. stock [NASDAQ: PROK] is trending down by -8.13%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

ProKidney’s Financial Snapshot

When it comes to trading, understanding market trends and adapting to changes is crucial. Successful traders know that flexibility and continuous learning are key. As millionaire penny stock trader and teacher Tim Sykes says, “You must adapt to the market; the market will not adapt to you.” By staying informed and ready to adjust their strategies, traders can better position themselves to capitalize on opportunities and mitigate risks in the ever-changing financial landscape.

The company’s finances paint a turbulent picture. ProKidney, while showing resilience in terms of assets with a substantial $406.06M total assets, still struggles with profitability. Its profit margins are significantly negative, indicating that expenses far outweigh their revenues. Notably, their revenue per share is a mere $0.0006, indicating very low earnings relative to their size.

Balance sheets show more depth. Around $360.84M in liabilities tie up the company, yet it holds significant current assets worth $359.66M. With a current ratio of 11, ProKidney has more than enough short-term assets to cover its short-term liabilities. However, their cash flow tells a different story: operating cash flow at -$29.59M showcases a gap between income and expenses, with significant cash absorbed by operating activities.

The sales of $76,000 might seem negligible, but when dissected within the broader scope of a company with a negative price-to-book value, it stresses potential underperformance relative to expectations. Will these financial layers fuel gains or serve as points of concern?

ProKidney’s Stock Turbulence: A Deeper Dive

Recent decisions and market actions have hit ProKidney hard. With a downgrade by BofA, the market reacted almost immediately. For a company like ProKidney that sails the choppy waters of pharmaceutical innovation, the anticipated sales of new therapeutic products can make or break future financial stability. The downgrade reflected conservative future sales for their therapy, REACT, crucial for tackling kidney diseases.

Uncertainty has always played a role in pharma stock movements, particularly with experimental products. The expected modest success of these therapies can reverse fortunes, but without it, a pessimistic outlook persists. Jittery investors have acted on these warnings.

Even the mere fact of substantial insider selling by an executive, Mr. Weber, creates waves. Such sell-offs can be perceived as a lack of conviction in the company’s upside potential, exacerbating price dips in the short term.

More Breaking News

Recap and Market Implications

A storm brews in ProKidney’s financial skies. As it stands, investor confidence is wavering. Stock actions such as insider selling, valuation cuts, and downgrades dominate investor conversations at this juncture. Might this see a domino effect of declining stock value before potential stabilization? It depends. Future earnings reports’ potential surprises and competitive advantages from their REACT product could light ProKidney’s path forward, but risks remain lush.

Navigating through such tumult, seasoned traders may see opportunity amid the noise, as historically undervalued or high-risk pharma stocks have occasionally turned back on mixed-high hopes of groundbreaking clinical outcomes. As millionaire penny stock trader and teacher Tim Sykes says, “Be patient, don’t force trades, and let the perfect setups come to you.” Is ProKidney another tale to unfold, or just a standard play of pharmaceutical unpredictability?

It’s yet another case study in the interplay of innovation, uncertainty, and trader sentiment, creating a dynamic that, once again, makes its mark in the world of stocks and performance gambles.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”